» Farmakologiczne leczenie jaskry© Borgis - Nowa Medycyna 2, s. 22-35
*Tomasz Mrozowski
Farmakologiczne leczenie jaskry
Pharmacological treatment of glaucoma
Apteka Szpitalna, Szpital im. M. Okońskiego, Warszawa
Kierownik Apteki: mgr farm. Tomasz Mrozowski Summary
Key words:
Piśmiennictwo
1. Mrozowski. T., Goś R.: Leki okulistyczne – kompendium. Wydawnictwo Lekarskie PZWL, 2000. 2. Quigley H.A.: Number of people with glaucoma. Br. J. Optalmol. 1996; 80: 389-93. 3. Cioffi G.A., Sullivan P.: The effect of chronic ischemia on the primate optic nerve. Euro. J. Ophtalmol. 1999; 9: 34-6. 4. Kass M.A.: Normal-pressure glaucoma. Am. J. Ophtalmol. 1998; vol 125: 242-4. 5. Tatton W.G.: Apoptopic mechanisms in neurodegeneration: Possible relevance to glaucoma. Europ. J. Ophtalmol. 1999; 9: 22-7. 6. Silver L.H. and the Brinzolamide Primary Therapy Study Group: Clinical efficacy and safety of Brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J. Ophtalmol. 1998; 126: 400-8. 7. Katz J. and Brimonidine Study Group: Brimonidine tartrate 0,2% twice daily vs timolol 0,5% twice daily: 1-year results in glaucoma patients. Am. J. Ophtalmol. 1999; 127: 20-6. 8. Strahlman E., et al, and the International Dorzolamide Study Group, A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol, Archiv. Ophtalmol. 1995; vol 113: 1009-16. 9. Coleen M., et al.: The Dorzolamide-Timolol Combination Study Group., A randomized trial in patients inadeguately controlled to monotherapy with timolol or dorzolamid, Ophtamol. 1998; vol. 105. 10. Watson P.G. and the Latanoprost Study Group. Latanoprost: two years´experience of its the United Kingdom. Ophtalomol. 1998; 105: 82-7. 11. Mishima H.K., et al.: A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. Archi. Ophatlmol. 1996; vol. 114: 929-32. 12. Schuman J.S.: Antiglaucoma medications: a review of safety and tolerability related to their use. Clinical Therapeutics 2000; 22: 167-208. 13. Wiederholdt M.: New aspects in aqueous humor dynamics. W: Pharmacotherapy in glaucoma. Verlag Hans Huber, Bern 2000; 65-72. 14. Prunte C., Markstein R.: Adrenergic regulation and its therapeutic aspects in the eye. In: Pharmacotherapy in glaucoma. Verlag Hans Huber, Bern 2000; 73-9. 15. Erb C.: Comparison of alfa-2-agonists: clonidine, apraclonidine, brimonidine. In: Pharmacotherapy in glaucoma. Verlag Hans Huber, Bern 2000; 115-26. 16. Messerli J.: Parasympathetic drugs in the eye. In: Pharmacotherapy in glaucoma. Verlag Hans Huber, Bern 2000; 127-36. 17. Pfeiffer N.: Carbonic anhydrase: pharmacology and inhibition. In: Pharmacotherapy in glaucoma. Verlag Hans Huber, Bern., 2000; 137-44. 18. Diestelhorst M.: Glaucoma treatment with latanoprost. In: Pharmacotherapy in glaucoma. Verlag Hans Huber, Bern 2000; 169-74. 19. Potter D.E.: Adrenergic pharmacology of aqueous humor dynamics. Pharmacol Rev 1981; 33: 133-49. 20. Czechowicz-Janicka K., Krajewska M., Terelak-Borys B.: Co nowego w diagnostyce i terapii jaskry? Postępy Nauk Medycznych 2001; XIV; 43-7. 21. Shields M.B.: Adrenergic stimulators. In: Textbook of glaucoma. Williams&Wilkins Baltimore 1992; 462-79. 22. Mittag T.W.: Adrenergic and dopaminergic drugs in glaucoma. In: The glaucomas. Mosby 1996; 1409-24.
otrzymano/received: 2007-05-30 zaakceptowano/accepted: 2007-06-04 Adres/address: *Tomasz Mrozowski Apteka Szpitalna, Szpital im. M. Okońskiego ul. Brzeska 12, 03-737 Warszawa tel. 0 692-784-978 e-mail: huba167@wp.pl Pełna wersja artykułu Farmakologiczne leczenie jaskry dostępna w Czytelni Medycznej Borgis. |